Effect of topical marshmallow ( Althaea officinalis ) on atopic dermatitis in children: A pilot double‐blind active‐controlled clinical trial of an in‐silico ‐analyzed phytomedicine

2020 ◽  
Author(s):  
Vahedeh Naseri ◽  
Zahra Chavoshzadeh ◽  
Azadeh Mizani ◽  
Babak Daneshfard ◽  
Farzaneh Ghaffari ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Atopic Dermatitis ◽  
In Silico ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Althaea Officinalis

scholarly journals A novel hydrocortisone-ethanol gel ointment for treating atopic dermatitis (eczema) in children: A double blind, randomized, controlled clinical trial

2019 ◽  
Vol 3 (1) ◽  
Author(s):  
Dale Lawrence Pearlman
Keyword(s):  
Clinical Trial ◽  
Atopic Dermatitis ◽  
Controlled Study ◽  
Controlled Clinical Trial ◽  
Severe Atopic Dermatitis ◽  
Double Blind ◽  
Parental Concerns ◽  
Score Improvement ◽  
Long Time ◽  
Secondary Endpoints

Importance: Current treatments for moderate to severe atopic dermatitis (AD) in children are limited by incomplete efficacy, long time to benefit, and parental concerns about safety. This study evaluated a novel ointment for treating AD containing 0.83% hydrocortisone and 17% dispersed ethanol gel micro bubbles.  Observations:20 children with moderate to severe AD participated in a one-week double blind, randomized, and controlled clinical trial. They were randomly assigned to apply BID either an ointment with 1% hydrocortisone ointment (HC) or a novel ointment containing 1% hydrocortisone and dispersed ethanol gel droplets (HC-EG).   The primary endpoint was superiority of HC-EG over HC ointment in SCORAD score improvement during therapy. A secondary endpoint was improvement in pruritus score during therapy. Both the primary and secondary endpoints were reached in this study. SCORAD score improved 74% on average with HC-EG ointment vs 41% with HC ointment (p=.02). Pruritus score improved 68% on average with HC-EG ointment vs 37% with HC ointment (p=.009). No toxicity requiring stopping therapy was observed in either treatment group.  Conclusions and Relevance: Inthis small controlled study HC-EG ointment was superior to HC ointment both in improving visible rash and pruritus of AD. Parents felt HC-EG ointment was safe because it contains no prescription corticosteroids, prescription immunosuppressants, or antibiotics. Independent larger studies would be a next step in evaluating further this new way to treat AD. 

Efficacy of Short Term Topical Malva Sylvestris L. Cream in Pediatric Patients with Atopic Dermatitis: A Randomized Double-Blind PlaceboControlled Clinical Trial

2020 ◽  
Vol 20 ◽  
Author(s):  
Mahshid Meysami ◽  
Mohammad Hashem Hashempur ◽  
Mohammad Kamalinejad ◽  
Majid Emtiazy
Keyword(s):  
Clinical Trial ◽  
Atopic Dermatitis ◽  
Primary Outcome ◽  
Primary Outcome Measure ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Malva Sylvestris ◽  
Topical Cream ◽  
Traditional Persian Medicine ◽  
Dermatologic Disease

Background: Atopic dermatitis (AD) is a chronic inflammatory pruritic dermatologic disease in children. Malva sylvestris L. (M. sylvestris) is a medicinal plant which is used as a remedy for eczema in traditional Persian medicine. Previous studies have shown anti‐ulcerogenic and anti‐inflammatory activity of this plant. Objectives: We designed a clinical trial to evaluate efficacy of topical cream of M. sylvestris extract in management of children with AD. Methods: Fifty one children with AD were randomly enrolled in two arms of a randomized, double-blind, controlled clinical trial. They were treated by topical cream of M. sylvestris extract or placebo for a palm-sized surface (single fingertip unit, twice daily) for 4 weeks. The SCORing Atopic Dermatitis (SCORAD) score was set as the primary outcome measure. Results: There was a significant improvement in the severity of participants’ dermatitis regarding skin thickening score, redness score, and total SCORAD score of the M. sylvestris group as compared with the placebo group (P= 0.009, P=0.01, and P=0.03; respectively). Conclusion: According to the results of this clinical trial, it could be concluded that topical use of M. sylvestris extract cream was effective on the reduction of the AD symptoms in children.

scholarly journals Randomized, double-blind, placebo-controlled clinical trial measuring the effect of a dietetic food on dermatologic scoring and pruritus in dogs with atopic dermatitis

2021 ◽  
Vol 17 (1) ◽  
Author(s):  
Miguel Sánchez de Santiago ◽  
José Luis González Arribas ◽  
Yolanda Moral Llamas ◽  
Iveta Becvarova ◽  
Hein Meyer
Keyword(s):  
Clinical Trial ◽  
Atopic Dermatitis ◽  
Control Diet ◽  
Clinical Signs ◽  
Controlled Clinical Trial ◽  
Omega 3 ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Study Results ◽  
Multimodal Management

Abstract Background Canine atopic dermatitis (AD) is a common condition that often requires multimodal therapy. Including a diet in the multimodal management of AD may reduce medication doses, saving pet owners money and reducing side effects. The objective of this randomized, double-blind, placebo-controlled clinical trial was to determine if a diet fortified in antioxidants, polyphenols, and omega-3 fatty acids can reduce the clinical signs of AD. Forty client-owned dogs with AD were enrolled in the study and assigned to either an enriched diet (diet B) or control diet (diet A) for 60-days. CADESI-4 index scores and owner-reported pruritus scores were measured periodically. Results Total CADESI-4 index scores for dogs eating diet B were lower on day 60 compared to baseline (P = 0.003). There was no statistical difference in scores for dogs eating diet A over a 60-day period. Diet B dogs had 25 and 49% reductions in CADESI-4 index scores on days 30 and 60, respectively (P = 0.0007) while diet A had no change over the study period. When comparing the percent change in owner-reported pruritus scores, diet B also performed better than diet A. By day 60, owners feeding diet B to their dogs reported a significant reduction (P < 0.0001) of 46.4% in itching, while those on diet A reported a 26.8% reduction, which was not statistically significant (P = 0.08). Conclusions These study results demonstrate feeding a diet enriched with ingredients to improve skin health and reduce inflammation improves the clinical signs of AD in dogs.

scholarly journals Efficacy of a probiotic supplement in patients with atopic dermatitis: a randomized, double-blind, placebo-controlled clinical trial

2021 ◽  
Vol 31 (2) ◽  
pp. 225-232
Author(s):  
Angela Michelotti ◽  
Enza Cestone ◽  
Ileana De Ponti ◽  
Silvana Giardina ◽  
Marta Pisati ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Atopic Dermatitis ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo

scholarly journals The Efficacy and Safety of Longmu Tang Granule for Treating Atopic Dermatitis: Study Protocol for a Single-Centered, Double-Blinded, Randomized Controlled Trial

2021 ◽  
Author(s):  
YAQIN LI ◽  
TAOTAO SHEN ◽  
QINGYING WANG ◽  
MENGXI MA ◽  
FENGYAN TIAN ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Atopic Dermatitis ◽  
Clinical Symptoms ◽  
Controlled Trial ◽  
Controlled Clinical Trial ◽  
Efficacy And Safety ◽  
Double Blind ◽  
Randomized Controlled ◽  
Limited Effectiveness

Abstract Background: Atopic dermatitis (AD) is a chronic relapsing skin disease that has long-term adverse effects on the physical and mental health of children. Current treatments mainly include anti-inflammatory, antibacterial, and anti-allergic interventions, systemic therapy and recently emerging targeted agents. However, these treatments have limited effectiveness and bothersome side effects. The use of traditional Chinese medicine (TCM) is associated with safety and improvements in the clinical symptoms and quality of life of AD patients. However, the poor quality and heterogeneity of studies have not led to sufficient conclusions. Therefore, we will conduct a randomized, controlled, double-blind clinical trial to confirm the efficacy and safety of Longmu Tang granule for the treatment of AD.Methods: This is a single-center, double-blind, randomized, controlled clinical trial. A total of 60 participants will be randomly assigned (1:1) to receive Longmu Tang granule or placebo granule for 8 weeks. The primary outcome is the index of Scoring Atopic Dermatitis (SCORAD). The second outcomes include the children's Dermatology Life Quality Index (CDLQI) and the Number Cancel Test (NCT), and long-term efficacy. Mechanistic outcome is the serum level of inflammatory cytokines, including IgE, tumor necrosis factor (TNF) -α, interleukin-1 (IL-1) and interleukin-6 (IL-6).Discussion: The results of this trial will provide evidence on the efficacy and safety of Longmu Tang granule and prove anti-inflammation of Longmu Tang granule for patients with AD.Trial registration: Chinese Clinical Trial Registry Chictr.org ID: ChiCTR2100041591. Registered on 1 January 2021. https://www.chictr.org.cn/showproj.aspx?proj=62586

scholarly journals Therapeutic effectiveness of Lishi Oral Liquid combined with levocetirizine in treating atopic dermatitis: A randomized double-blind placebo-controlled clinical trial

2019 ◽  
Vol 02 (04) ◽  
pp. 179-183
Author(s):  
Jingxiu Chai ◽  
Jie Ren ◽  
Kexiang Yan ◽  
Feng Xu ◽  
Ying Ma ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Atopic Dermatitis ◽  
Life Quality ◽  
Chinese Herbs ◽  
Control Group ◽  
Controlled Clinical Trial ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Oral Liquid ◽  
And Control

Objective: To observe the efficacy and safety of Lishi Oral Liquid (LOL), a Chinese herbs formula, combined with levocetirizine, an antihistamine drug, in patients with damp-heat atopic dermatitis (AD). Methods: A randomized double-blind placebo-controlled clinical trial was conducted. Ninety patients diagnosed with damp-heat atopic dermatitis were randomly assigned to Lishi Oral Liquid group and control group at the ratio of 1:1. Patients were given one Lishi Oral Liquid or placebo three times per day. Both groups were treated with allantoin and vitamin E cream by topical use and levocetirizine by oral administration. Patients were followed up at the second and fourth week. The primary outcome was the scoring of atopic dermatitis (SCORAD). The secondary outcomes were visual analogue scale (VAS) and dermatology life quality index (DLQI). Results: After two weeks of treatment, there were statistical differences in SCORAD between these two groups ([Formula: see text]), whereas VAS and DLQI showed no statistical differences. There were significant differences in SCORAD and VAS between two groups at the end of four weeks of treatment ([Formula: see text]). However, no significant differences were observed in DLQI after four weeks of treatment. No serious adverse event was found during this clinical trial. Conclusion: LOL combined with levocetirizine is effective and safe for damp-heat AD treatment.

Sign in / Sign up

Export Citation Format

Share Document